Citations

Clear

1417 citation(s) found for "Simon, FM".

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants
So, Isis , Staffaroni, Adam M. , Coleman, Kristy , Bouzigues, Arabella , Ferry‐Bolder, Eve , Cullen, Eva , Russell, Lucy L. , Foster, Phoebe H. , Farley, Sophie , Thompson, Alexander, Ber, Isabelle Le , Körtvelyessy, Péter , Schroeter, M., Uzelac, Željko , Kruger, Johanna S. W. , Langheinrich, Tobias , Ducharme, Simon , Santana, Isabel J., Tartaglia, Carmela, Mendonca, Alexandre de, Morenoizco, Fermin, Brushaber, Danielle, Considine, Ciaran , Faber, Kelley, Fagan, Anne, Fields, Julie, Foroud, Tatiana, Forsberg, Leah K. , Geschwind, Daniel, Heuer, Hilary W. , Huang, Eric, Kantarci, Kejal, Kolander, Tyler , Lago, Argentina Lario , Lavigne, Shannon B., Mester, Carly , Molden, Joie, Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eilana, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Weintraub, Sandra, Wong, Bonnie, Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Lombardi, Jolina , Staffaroni, Adam M , Coleman, Kristy K L , Bouzigues, Arabella , Ferry-Bolder, Eve , Cullen, Eva , Russell, Lucy L , Foster, Phoebe H , Farley, Sophie , Convery, Rhian , Van Swieten, John C , Jiskoot, Lize C , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Bruffaerts, Rose , Bertoux, Maxime , Lebouvier, Thibaud , Solje, Eino , Xiong, Chengjie , di Fede, Giuseppe , Le Ber, Isabelle , Migliaccio, Raffaella Lara , Körtvélyessy, Peter , Logroscino, Giancarlo , Otto, Markus , Uzelac, Zeljko , Illán-Gala, Ignacio , Krüger, Johanna , Nacmias, Benedetta , Gerhard, Alexander , Langheinrich, Tobias , Ducharme, Simon , Masellis, Mario , Rowe, James B , Graff, Caroline , Synofzik, Matthis , Borroni, Barbara , Sánchez-Valle, Raquel , Considine, Ciaran M , Forsberg, Leah K , Gendron, Tania F , Heuer, Hilary W , Huang, Eric , Kolander, Tyler , Mester, Carly , Petrucelli, Leonard , Rademakers, Rosa , Vandebergh, Marijne , Boeve, Brad , Boxer, Adam , Rosen, Howard J , Lee, Suzee E , Rohrer, Jonathan D , Finger, Elizabeth C. , Lombardi, Jolina , Swieten, John C. van , Jiskoot, Lize C. , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Lebouvier, Thibaud , Xiong, Chengjie , Thompson, Alexander G. , Logroscino, Giancarlo , Otto, Markus , Illán‐Gala, Ignacio , Nacmias, Benedetta , Tartaglia, Carmela M., de Mendonça, Alexandre , Rowe, James B. , Graff, Caroline , Moreno, Fermín , Synofzik, Matthis , Borroni, Barbara , Sánchez‐Valle, Raquel , Brushaber, Danielle , Fagan, Anne M. , Gendron, Tania F. , Geschwind, Daniel, Kantarci, Kejal , Ramos, Eliana Marisa , Rankin, Katherine P. , Vandebergh, Marijne , Weıntraub, Sandra , Boeve, Bradley F. , Rohrer, Jonathan D.

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.08.26355165 | PMID 42326777 Get It

ABSTRACT Background and Objectives Converging evidence hints at neurodevelopmental effects in genetic frontotemporal degeneration (FTD). In cross-sectional studies, for some genes, young adult FTD variant carriers show differences in brain volumes and cognition compared to familial non-carriers. However, longitudinal trajectories may more sensitively capture FTD-related neurodevelopmental vs. neurodegenerative changes than cross-sectional approaches. This study examined longitudinal trajectories of brain volumes, executive function, and plasma biomarkers in young adult carriers compared to familial non-carriers, as measures of neurodevelopmental and neurodegenerative outcomes of FTD-causing variants. Methods This longitudinal cohort study comprised participants, aged 18-30 years, from the FTD Prevention Initiative across Europe, Canada, and the USA. Genetic groups included C9orf72 (47%), MAPT (30%), and GRN (23%). Linear mixed-effects models were computed to assess longitudinal outcomes across age between groups, controlling for sex, scanner (for brain volumes), and education (for executive function); random effects accounted for between-subject variability nested within family membership. Results Variant carriers ( n =147) and familial non-carriers ( n =113) did not differ in age (mean±SD, 25.9±3.2 years), sex (53% female), or number of visits (2.1±1.7). Young adult C9orf72 repeat expansion carriers exhibited smaller thalamic volumes than non-carriers at the reference age of 26 years ( b =-982.8mm 3 , SE=317.0, p= 0.0046, f 2 =0.32), with relatively stable trajectories across ages 18-30 (i.e., no change over time). Trajectories of rostral anterior cingulate volumes differed in C9orf72 carriers and non-carriers across age, where carriers showed relatively stable trajectories and non-carriers showed age-appropriate declines ( b =64.4mm 3 , SE=29.9, p= 0.035, f 2 =0.07). For MAPT and GRN , there were little to no differences in total brain, cortical, or subcortical volumes between groups and over time. No longitudinal differences were observed between carriers and non-carriers in executive function, or plasma NfL or GFAP for any genetic group. Discussion C9orf72 repeat expansions were linked to smaller average thalamic volumes and stable trajectories between ages 18 to 30, supporting potential neurodevelopmental origins. The modest evidence supporting an absence of difference in neurodegenerative biomarkers and executive function suggests minimal early neurodegeneration and functional preservation in young adulthood.
Persistence to Botulinum Toxin and Factors Associated With Discontinuation: A Retrospective Cohort Study (P5-14.010)
Wainberg, Michael, Zhang, Jinming, Page, Simon, Bouchard, Jonathan, Mann, Amandeep, BENETEAU, Mathieu, Schultz, Billie, Zhang, Jinming , Page, Simon , Mann, Amandeep, Beneteau, Mathieu , Schultz, Billie A.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216901 Get It

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial
Khanna, D, Korman, David S., Mease, Philip, Griffith, Melissa, Carpintero, Maria , Wener, Mark H. , Kramer, Neil , Schett, G, Mayes, Maureen D., Melton, Alexis, Handy, Whitney, Ou, San-San, Jarugula, Praneeth , Ide, Takafumi , Harnois, Melissa, Thorpe, Jerill , Koegel, Ashley, Wiesendanger, Margrit, Harnois, Melissa J. , Khanna, Dinesh , Majithia, Vikas , Bernstein, Elana J. , Mease, Philip J. , Simon, David , Schett, Georg , Gómez‐García, Ignacio , Mayes, Maureen D. , Desai, Alisha, Handy, Whitney, Ou, San‐San , Ide, Takafumi, Koegel, Ashley K., Wiesendanger, Margrit

Mayo Clinic

Oral Communications | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: A61-A63

10.1136/jsrd-2026-sswc.57 Get It

A Structured Consent Framework for Research of Electroconvulsive Therapy in Advanced Dementia
Holzman, Andrew L., Forester, Brent P. , Sanghani, Sohag , Hermida, Adriana P., Petrides, Georgios, Nykamp, Louis, Kung, Simon , Williams, Sarah , Pagali, Sandeep R. , Lapid, Maria I. , Holzman, Andrew E. , Wilkins, James M. , Hermida, Adriana P., Mueller, Martina , Patrick, Regan , Gentry, Melanie T

Mayo Clinic

The Journal of ECT | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/yct.0000000000001296 | PMID 42240217 Get It

Objectives: The electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD) trial is a multisite study evaluating the effectiveness of ECT for severe agitation in individuals with advanced dementia. Given that participants lack decisional capacity because of advanced cognitive impairment, the trial required a structured and ethically sound approach to obtaining informed consent and assent across jurisdictions with differing legal requirements, including Massachusetts, New York, Georgia, Minnesota, and Michigan. This paper describes the approach used in the study. Methods: We describe the consent framework developed for the ECT-AD trial, including procedures for identifying legally authorized representatives, complying with state-specific laws for ECT consent, obtaining surrogate consent for research participation, and assessing patient assent and dissent using a standardized tool. Conclusions: The approach used in this study may serve as a practical model for future research involving individuals without decision-making capacity and legally complex interventions such as ECT.
Pediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices
Ramantani, Georgia , Cross, J. Helen , Cserpán, Dorottya , Ahemad, Emtnan , Aparicio, Javier , Arzimanoglou, Alexis , Barba, Carmen , Bingaman, William , Braun, Kees , Burman, R J, Cai, Lixin , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cukiert, Cristine Mella , Dal, Sameer , Englot, Dario, Enright, Noelle , Sorbets, Sarah Ferrand , Mahecha, Laura Guio, Hallböök, T , Harvey, A. Simon, Holthausen, H, Jiang, Y , Kannan, Lakshminarayanan , Lallas, Matt, Valappil, Ahsan Moosa Naduvil , Patil, Sandeep Bhagwan , Pieper, Tom , Tripathi, Manjari , Vendégh, Lejla, Weiner, Howard , Wilmshurst, Jo, Smith, MK, Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Wilmshurst, Jo M. , Burman, Richard J. , Shetty, Jay , Burman, Richard J , Butler, James , Cai, Li-Xin , Cao, Dezhi , Caraballo, Roberto H , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cukiert, Arthur , Dal, Sameer , Englot, Dario J , Enright, Noelle , Fallah, Aria , Ferrand Sorbets, Sarah , Feucht, Martha , Gill, Deepak , Hadjinicolaou, Aristides , Harvey, A Simon , Holthausen, Hans , Jiang, Yuwu , Kannan, Lakshminarayanan , Katlowitz, Kalman A , Kotulska-Jóźwiak, Katarzyna , Kudr, Martin , Lallas, Matt , Patil, Sandeep Bhagwan , Specchio, Nicola , Tripathi, Manjari , Wilmshurst, Jo M , Smith, Mary Lou , Wirrell, Elaine C , Ramantani, Georgia , Cross, Helen J , Shetty, Jay , Barba, Carmen , Braun, Kees P. J. , Englot, Dario J. , Fallah, Aria , Feucht, Martha , Moosa, Ahsan N. , Specchio, Nicola , Wirrell, Elaine

Mayo Clinic

Epilepsia | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70312 | PMID 42227967 Get It

Abstract Objective Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were <1 year old (highest in Oceania: 5.1%), and 6.1% were nonpharmacoresistant (highest in Europe: 15.0%). Prior neurosurgery was reported in 14.2% (highest in North America: 28.8%), including 8.0% resections (6.1% for epilepsy, 1.5% for tumors; highest in Oceania: 16.5%), 2.3% disconnections (1.3% corpus callosotomy; highest in South America: 4.7%), and 4.2% neuromodulation (3.7% vagal nerve stimulation, .2% responsive neurostimulation, one deep brain stimulation; highest in North America: 12.2%). Developmental and epileptic encephalopathies (DEEs) at surgery included Lennox–Gastaut syndrome (7.4%), infantile epileptic spasms syndrome (5.1%), and DEE with spike–wave activation in sleep (1.5%). Presurgical investigations included fluorodeoxyglucose positron emission tomography (52.6%; highest in Oceania: 79.7%), genetic testing (46.8%; highest in Asia: 54.3%), magnetic resonance imaging (MRI) postprocessing (32.4%; highest in South America: 53.0%), functional MRI (fMRI; 15.2%; highest in North America: 40.3%), magnetoencephalography (11.9%; highest in North America: 39.3%), single photon emission computed tomography (9.6%; highest in North America: 22.2%), high‐density electroencephalography (EEG; 1.9%; highest in Europe: 4.7%), source localization (1.6%; highest in Oceania: 7.6%), Wada test (1.2%; highest in North America: 3.5%), and EEG‐fMRI (.5%; highest in Europe: 1.1%). Significance Despite some early surgeries, including in infancy and before pharmacoresistance, mean epilepsy duration before surgery remains >5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.
Real-world impact of a sepsis early detection model integrated into clinical workflow: a quasi-experimental study
Zhang, Yifan , Trinh, Sarolta H., Phelan, Tom, Byrd, Thomas F., Tourani, Roshan , Kumar, Vipin , Melton, Genevieve B., Simon, György , Trinh, Sarolta Haiyen , Phelan, Tom, Byrd, Thomas F. , Caraballo, Pedro J. , Melton, Genevieve B.

Mayo Clinic

No container title available | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.22.26353890 Get It

Abstract Background Sepsis is a life-threatening condition in which delayed recognition and treatment are associated with increased mortality. While predictive models such as Epic’s Early Detection of Sepsis Model (ESM) were developed to support early intervention, their real-world impact after integration into clinical workflows remains difficult to evaluate. Objectives To evaluate the real-world impact of ESM integrated into clinical workflow on clinical outcomes, antibiotic use, and harm-benefit tradeoffs. Methods We conducted a quasi-experimental study in a single healthcare system using encounter-level data from inpatient settings. Inpatient mortality, prolonged hospitalization, antibiotic use, and sepsis prevalence were compared between the pre-implementation period (3 June 2023 to 20 August 2024) and the online period (21 August 2024 to 26 December 2024) when the model became visible to clinicians. We also applied a counterfactual framework using models trained on pre-implementation data to estimate expected outcomes without ESM and to quantify harms related to overtreatment and delayed treatment. Results Among 101,138 encounters, 86,884 occurred during the pre-implementation period and 14,254 during the online period. In unadjusted analyses, the online period had lower inpatient mortality, prolonged hospitalization, antibiotic use, and sepsis prevalence (all p≤0.002). In the counterfactual analyses, observed outcomes were lower than expected without ESM for mortality (1.21% vs 1.82%; p<0.001), prolonged hospitalization (5.56% vs 7.95%; p<0.001), and antibiotic use (43.52% vs 47.04%; p<0.001). False positive harm (37.72% vs 41.68%; p<0.001) was also lower than expected. Conclusions Integration of ESM into clinical workflow was associated with improved patient outcomes, reduced antibiotic use, and decreased harm from overtreatment, without evidence of increased harm from delayed treatment, supporting a positive net clinical benefit and the safety and effectiveness of ESM under Software as a Medical Device principles.
Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, Sofia , Xiong, Grace , Murrell, Dedee Frances, Mueller, Simon M. , Mohandesi, Nessa Aghazadeh, Aldhaheri, Ahmed Salem, Asayag, Nissim, Baselga, Eulalia, Nadler, Chen , Chu, Chia‐Yu , Edminister, John R. , Guenova, Emmanuella, Gönülal, Melis , Gostynski, Antoni, Gupta, Lalit Kumar, Mazereeuw‐Hautier, Juliette, Hoetzenecker, Wolfram , Itin, Peter, Jankowski, Marek , Medvecz, Márta, Moosbrugger‐Martinz, Verena , Paller, Amy S., Plázár, Dóra , Queiróz, Amadeu José Rodrigues , Riera‐Monroig, Josep , Rosa, Ralph, Schmuth, Matthias, Freire, Maella Severino , Shabat, Itzhak, Shapiro, Jonathan , Soto‐García, Diego , Stratigos, Alexander J., Tadini, Gianluca Abel, Takeichi, Takuya , Verma, Kaushal K. , Wikström, Jakob D. , Ziv, Michael , Dodiuk‐Gad, Roni Pircha, Xiong, Grace , Mueller, Simon M , Ezzedine, Khaled , Choate, Keith , Gostynski, Antoni , Gupta, Ankan , Hoetzenecker, Wolfram , Jankowski, Marek , Kubo, Akiharu , Lee, Haur Yueh , Lehman, Julia Scott, Mellerio, Jemima E , Queiróz, Amadeu José Rodrigues , Freire, Maella Severino , Shapiro, Jonathan , Soto-García, Diego , Takeichi, Takuya , Wikström, Jakob D , Zink, Alexander , Navarini, Alexander , Hovnanian, Alain , Murrell, D F , Aghazadeh, Nessa , Aldhaheri, Ahmed S., Guenova, Emmanuella , Gönülal, Melis , Mazereeuw‐Hautier, J. , Lehman, Julia S. , Lepekhova, Anfisa A. , Medvecz, Márta, Paller, Amy S. , Schmuth, Matthias , Simpson, Cory L. , Tadini, Gianluca , Wikström, Jakob D. , Dodiuk‐Gad, Roni P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70483 | PMID 42223188 Get It

Abstract Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.
The impact of adjusting for c-Kit exon 11 mutation status when comparing prognostic models for gastrointestinal stromal tumors for prediction of recurrence.
Carfagnini, Christina, Bothara, Rishi, Bechara, Simon, Wattelet, Matthew, Sy, Nene, Majcher, Alex, RAFA, ZAHIN ISLAM , Gerstner, Gregory J. , Carfagnini, Christina L. , Sun, Chenyu , Bechara, Simon, Wattelet, Matthew P, Kandula, Manasa

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e23510 Get It

e23510 Background: There is minimal data comparing the prognostic models (PM) developed to predict recurrence of Gastrointestinal stromal tumors (GIST). Current PM include tumor size, location, and mitotic index (MI) but lack genotypic data. This analysis compares the performance of the National Institute of Health, Armed Forces Institute of Pathology, and Memorial Sloan Kettering Cancer Center models for predicting tumor recurrence with and without adjustment for c-kit Exon 11 mutation status (MS). Methods: This is an IRB-approved single-institution retrospective analysis. Adults with GIST mentioned in their medical records from 2014 – 2025 at the authors’ institution were identified. 330 patients with documented biopsy-proven GIST were included. Data was collected by manual review. PM were evaluated using multivariate analysis, adjusting for surgical resection, systemic therapy, and c-Kit exon 11 MS. Predictive performance was measured by area under the curve (AUC) and receiver operating characteristics (ROC) analysis. Results: Mean age at diagnosis was 64.6 years (SD =13.1 years). 46.7 % of patients were male. Primary GIST was most common in the stomach (63.9%) and small bowel (23.6%). Primary tumors were an average of 6.5 cm (SD 5.6 cm) with a MI of 6.6/50 HFU (SD = 13.4 50/HFU). Patients received resection (80.9%) and first-line systemic therapy with imatinib (43.3%). Recurrence occurred in 17.9% of patients. 19.4% of patients completed genetic testing, of which 51.6% were c-Kit exon 11 mutation positive. The predictive performance of all PM was not statistically different with (p value = 0.16) or without (p value = 0.18) adjustment for c-Kit exon 11 MS (Table 1). However, adjusting for c-Kit exon 11 MS improved AUC for all PM. Conclusions: Adjusting PM for c-KIT exon 11 status improved the predictive performance of all PM, although the results were not significant. This study found no significant difference in the performance of PM that predict GIST recurrence, which aligns with the one other study on this topic. Lack of significance may be due to a small sample size, which also limited the multivariate analysis. Including genotypes in PM that predict GIST recurrence should be further explored with larger multi-center datasets that can adjust for multiple mutations. Multivariate analysis comparing prognostic models for gastrointestinal stromal tumors at predicting recurrence with and without adjustment for c-KIT exon 11 genotypes using receiver operating characteristic. Without c-Kit exon 11 AUC (95% Confidence Interval) P value NIH 0.86 (0.81,0.90) 0.18 AFIP 0.87 (0.82,0.91) MSKCC 0.89 (0.84,0.94) With c-Kit exon 11 genotype NIH 0.80 (0.67,0.93) 0.16 AFIP 0.84 (0.73,0.95) MSKCC 0.90 (0.80,0.99) NIH: National Institute of Health, AFIP: Armed Forces Institute of Pathology, MSKCC: Memorial Sloan Kettering Cancer Centre. AUC: Area under the curve.
Phase 2 study of intratumoral oncolytic VV1 plus cemiplimab: Simon's stage 1 results from head and neck squamous cell carcinoma (HNSCC) cohort.
Powell, Steven , Nguyen, Anna C., Bayne, Harry E. Fuentes, Price, Katharine A. , Kern, Ryan, Fazer-Posorske, Casey, Anderson, D K, Baral, Binav, Boughton, Jennifer, Russell, Luke, Wiegert, Erol , Lowy, Israel , Seebach, Frank, Bexon, Alice, McGarrah, Patrick W. , Adamo, Daniel A. , Kern, Ryan , Fazer-Posorske, Casey , Boughton, Jen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e18026 Get It

e18026 Background: Immune checkpoint inhibitor (ICI) therapy is part of standard of care first-line therapy for recurrent or metastatic (R/M) HNSCC. However, less than 20% of patients (CPS ≥1) have an objective response to ICI monotherapy, and most tumors progress within ~3 months. We sought to improve the proportion of patients who benefit from a chemotherapy-free regimen by combining intratumoral (IT) VV1 oncolytic virus (VSV-IFNβ-NIS) injections with the anti-PD-1 antibody, cemiplimab. We report a pre-planned analysis of Simon's stage 1 results. Methods: We activated a phase 2 study testing the efficacy of first line IT VV1 plus cemiplimab in 1 st line patients with R/M HNSCC. A Simon's two-stage design was employed whereby 10 patients would be accrued in stage 1, and if 3 or more responses were observed, 12 additional patients would be accrued for stage 2. The primary endpoint was objective response rate (ORR) per investigator (RECIST 1.1). Eligible patients had untreated R/M HNSCC from primary oropharynx, oral cavity, hypopharynx, or larynx sites with CPS ≥1. Patients had to have at least one measurable lesion amenable to IT injection. Treatment comprised of IT injections to 1-5 lesions of oncolytic VV-1 virus and IV cemiplimab 350 mg on day 1, repeated every 21 days. Each lesion could be injected 3 times; a 4th injection was allowed if a partial response (PR) was achieved after 3 injections. Cemiplimab could be continued for up to 2 years until progression or unacceptable toxicity. Results: Patient and tumor characteristics, as well as efficacy and toxicity are summarized in the table below. Ten patients were treated at the time of Stage 1 analysis, with 3 showing a confirmed PR for ORR of 30%. Responder CPS scores were 45, 12 and 20%. Two of the responders subsequently showed progression after 6.2 and 9.9 months, the third has maintained PR at 7.7 months to date. Eight of 10 patients showed decrease in the sum of target lesion size (mean decrease of 16%; range -57 to 77%). One grade 2 event of ICI nephritis resolved with corticosteroid treatment. Conclusions: Three patients showed confirmed PR by RECIST 1.1 in Simon's stage 1, meeting criteria to proceed to Simon's stage 2. A total of 22 patients in the HNSCC will be enrolled. VV1 plus cemiplimab shows promise in first line R/M HNSCC based on these initial results. Clinical trial information: NCT04291105 . Patient demographics. N (treated) 10 Sex 20% female Median age (y) 60 (54 – 76) Oropharynx 7 HPV+ 7 Oral cavity 3 PD-L1 CPS median (range) 7.5 (1-45%) Locoregional injection 3 Distant injection 6 Local and distant injection 1 Best response (RECIST 1.1) PR 3 SD 5 PD 2 Adverse Events #pts any VV1/cemiplimab-related G3 AE 4 Lymphopenia 3 Elevated ALK 1